Since the Hormone Replacement Therapy market was destroyed almost overnight in 2002, there has been a lot of caution about investing in companies with a focus on women’s health. Mary Kerr, CEO of KaNDy Therapeutics and NeRRe Therapeutics, knows this only too well, but has not let it deter her in her quest to bring a treatment for symptoms of the menopause to the market.| Labiotech.eu
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive industry innovation.| Labiotech.eu
From groundbreaking immunotherapies to AI diagnostics and new vaccines, explore the innovations shaping the future of cancer treatment.| Labiotech.eu
The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease?| Labiotech.eu
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.| Labiotech.eu
Here are eight nanotechnology companies that are widening the scope in medicine, that you should know about.| Labiotech.eu
mRNA vaccines have been used for cancer therapies as well as for protection from infectious diseases, particularly for COVID-19.| Labiotech.eu
Discover promising advancements in oncology clinical trials presented by experts and biotechs from around the globe at ASCO 2024.| Labiotech.eu
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.| Labiotech.eu
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.| Labiotech.eu
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.| Labiotech.eu